Comorbidity in Irritable Bowel Syndrome

Whitehead, William E.; Palsson, Olafur S.; Levy, Rona R.; Feld, Andrew D.; Turner, Marsha; Von Korff, Michael
December 2007
American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2767
Academic Journal
BACKGROUND: Comorbid nongastrointestinal symptoms account for two-thirds of excess health-care costs in irritable bowel syndrome (IBS). OBJECTIVES: To determine whether IBS patients are at greater risk for specific comorbid disorders versus showing a general tendency to overreport symptoms; whether patients with inflammatory bowel disease (IBD) show patterns of comorbidity similar to IBS; whether comorbidity is explained by psychiatric disease; and whether excess comorbidity occurs in all IBS patients. METHODS: All 3,153 patients in a health maintenance organization with a diagnosis of IBS in 1994–1995 were compared to 3,153 age- and gender-matched controls, and to 571 IBD patients. All diagnoses in a 4-yr period beginning 1 yr before their index visit were categorized as gastrointestinal, psychiatric, or nongastrointestinal somatic. Nongastrointestinal somatic diagnoses were further divided into symptom-based versus biological marker-based diagnoses. RESULTS: Forty-eight of 51 symptom-based and 16 of 25 biomarker-based diagnoses were significantly more common in IBS versus controls. However, there were no unique associations. Bacterial, viral, and fungal infections and stroke were among diagnoses made more frequently in IBS. IBD patients were similar to controls. Greater somatic comorbidity was associated with concurrent psychiatric diagnosis. Only 16% of IBS patients had abnormally high numbers of comorbid diagnoses. CONCLUSIONS: Comorbidity in IBS is due to a general amplification of symptom reporting and physician consultation rather than a few unique associations; this suggests biased symptom perception rather than shared pathophysiology. Comorbidity is influenced by, but is not explained by, psychiatric illness. Excess comorbidity is present in only a subset of IBS patients.


Related Articles

  • Opioid Bowel Dysfunction and Narcotic Bowel Syndrome: A Population-Based Study. Rok Seon Choung; Locke, G. Richard; Zinsmeister, Alan R.; Schleck, Cathy D.; Talley, Nicholas J. // American Journal of Gastroenterology;May2009, Vol. 104 Issue 5, p1199 

    OBJECTIVES:Opioid prescription use is increasing. Narcotic bowel syndrome (NBS) refers to chronic abdominal pain aggravated by narcotic use. Despite increasing narcotic use, NBS may be under-recognized. The aim of this study was to assess whether gastrointestinal (GI) symptoms in the community...

  • Gastroenterology. Dalrymple, Jamie // Pulse;5/12/2010, Vol. 70 Issue 16, p26 

    The article offers information on various developments related to gastroenterology in Great Britain. It states that measuring calprotectin levels is a promising way to diagnose inflammatory bowel diseases (IBDs), and the 2008 NICE guidelines introduced new approaches to the diagnosis and...

  • Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. Santos, Javier; Alonso, Carmen; Vicario, María; Ramos, Laura; Lobo, Beatriz; Malagelada, J.-Ramón // Current Molecular Medicine;Jun2008, Vol. 8 Issue 4, p258 

    Inflammatory bowel disease (IBD) and the irritable bowel syndrome (IBS) are common causes of medical consultation and the most frequent diagnosis raised by gastroenterologists. Recent years have witnessed considerable advances in the understanding of the mechanisms involved in the initiation and...

  • Improving the quality of GI care in GP surgeries. Dalrymple, Jamie // Pulse;9/8/2010, Vol. 70 Issue 25, p33 

    The article describes how the Improving Management in Gastroenterology study (IMAGE) set out to introduce quality criteria for four common conditions namely irritable bowel syndrome (IBS), gastro-oesophageal reflux disease (GORD), coeliac disease and inflammatory bowel disease (IBD). It...

  • JournalScan.  // Gut;May2010, Vol. 59 Issue 5, p691 

    The article discusses various research related to gastroenterology. L. Laine and colleagues found that capsule endoscopy's failure to show good clinical outcome was caused by reasons such as its inability to get tissue or deliver therapy. S. Soderlund and colleagues discovered that inflammatory...

  • Quality of Life Measurement in Gastroenterology: What Is Available? Yacavone, Robert F.; Locke, Richard; Provenzale, Dawn T.; Eisen, Glenn M. // American Journal of Gastroenterology;Feb2001, Vol. 96 Issue 2, p285 

    Monitoring and enhancement of a patient's health-related quality of life (HURL) is an important element of research and medical care. In a previous article, we provided an overview of HURL measurement. Now we will review the structure and properties of the most commonly used generic and...

  • Irritable Bowel Syndrome May Be Associated with Maternal Inheritance and Mitochondrial DNA Control Region Sequence Variants. Tilburg, Miranda; Zaki, Essam; Venkatesan, Thangam; Boles, Richard // Digestive Diseases & Sciences;Jul2014, Vol. 59 Issue 7, p1392 

    Background and Aim: Mitochondrial dysfunction has been implicated in various functional disorders that are co-morbid to irritable bowel syndrome (IBS) such as migraine, depression and chronic fatigue syndrome. The aim of the current case-control pilot study was to determine if functional...

  • Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission. Jelsness-Jørgensen, Lars-Petter; Bernklev, Tomm; Moum, Bjørn // Gastroenterology Research & Practice;2013, p1 

    Background and Aim. In the inflammatory bowel diseases (IBDs), many symptoms are similar to the functional disorder irritable bowel syndrome (IBS). A challenge is thus to distinguish symptoms of IBD from IBS.The aim of this study was to investigate the levels of calprotectin in IBS-positive IBD...

  • Increased faecal serine protease activity in diarrhoeic lBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gecse, K.; Aóka, A.; Ferrier, L.; Leveque, M.; Eutamene, H.; Cartier, C.; Aet-Belgnaoui, A.; Rosztóczy, A.; Izbéki, F.; Fioramonti, J.; Wittmann, T.; Bueno, L. // Gut;May2008, Vol. 57 Issue 5, p591 

    OBJECTIVES: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is characterised by elevated colonic lumenal serine protease activity. The aims of this study were (1) to investigate the origin of this elevated serine protease activity, (2) to evaluate if it may be sufficient to trigger...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics